{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:38:06Z","timestamp":1790793486770,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004505","name":"Universit\u00e0 degli Studi di Catania","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004505","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s13311-021-01037-2","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T11:22:39Z","timestamp":1618226559000},"page":"1166-1174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-3135","authenticated-orcid":false,"given":"Aurora","family":"Zangh\u00ec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Petracca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bonavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buccafusca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Callari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pontillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Abbadessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Di Francescantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Lus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Sola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Granella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Mirabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-9057","authenticated-orcid":false,"given":"Emanuele","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01037-2_bib1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.6061\/clinics\/2015(07)10","article-title":"Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: a meta-analysis","volume":"70","author":"Yin","year":"2015","journal-title":"Clinics (Sao Paulo, Brazil)."},{"key":"10.1007\/s13311-021-01037-2_bib2","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01037-2_bib3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s40264-016-0461-6","article-title":"Treatment-related progressive multifocal leukoencephalopathy in multiple sclerosis: a comprehensive review of current evidence and future needs","volume":"39","author":"D'Amico","year":"2016","journal-title":"Drug Safety."},{"key":"10.1007\/s13311-021-01037-2_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1586\/14737175.2014.874947","article-title":"We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?","volume":"14","author":"Fragoso","year":"2014","journal-title":"Expert review of neurotherapeutics."},{"key":"10.1007\/s13311-021-01037-2_bib5","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01037-2_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.autrev.2018.09.012","article-title":"A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis","volume":"18","author":"Sellner","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1007\/s13311-021-01037-2_bib7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jamaneurol.2017.0357","article-title":"Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes","volume":"74","author":"Zhao","year":"2017","journal-title":"JAMA neurology."},{"key":"10.1007\/s13311-021-01037-2_bib8","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Annals of neurology."},{"key":"10.1007\/s13311-021-01037-2_bib9","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Annals of neurology."},{"key":"10.1007\/s13311-021-01037-2_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther Adv Neurol Disord."},{"key":"10.1007\/s13311-021-01037-2_bib11","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01037-2_bib12","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1136\/jnnp-2017-316236","article-title":"Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events","volume":"88","author":"Calabrese","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01037-2_bib13","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1212\/WNL.0000000000000283","article-title":"Fingolimod after natalizumab and the risk of short-term relapse","volume":"82","author":"Jokubaitis","year":"2014","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01037-2_bib14","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1586\/14737175.2016.1168295","article-title":"Disease activity return after natalizumab cessation in multiple sclerosis","volume":"16","author":"Rasenack","year":"2016","journal-title":"Expert Rev Neurotherapeutics"},{"key":"10.1007\/s13311-021-01037-2_bib15","doi-asserted-by":"crossref","unstructured":"D'Amico E, Patti F, Zangh\u00ec A, Zappia M. A personalized approach in progressive multiple sclerosis: the current status of disease modifying therapies (DMTs) and future perspectives. Int J Mol Sci 2016;17.","DOI":"10.3390\/ijms17101725"},{"key":"10.1007\/s13311-021-01037-2_bib16","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00415-016-8207-z","article-title":"Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study","volume":"263","author":"D'Amico","year":"2016","journal-title":"J Neurol."},{"key":"10.1007\/s13311-021-01037-2_bib17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/14737175.2015.1058162","article-title":"Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal","volume":"15","author":"D'Amico","year":"2015","journal-title":"Expert Rev Neurotherapeutics"},{"key":"10.1007\/s13311-021-01037-2_bib18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.autrev.2019.05.003","article-title":"Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives","volume":"18","author":"D'Amico","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1007\/s13311-021-01037-2_bib19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10072-017-3228-7","article-title":"Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help?","volume":"39","author":"Mancinelli","year":"2018","journal-title":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology."},{"key":"10.1007\/s13311-021-01037-2_bib20","doi-asserted-by":"crossref","unstructured":"M\u00f6hn N, Skripuletz T, S\u00fchs KW, Menck S, Vo\u00df E, Stangel M. Therapy with cladribine is efficient and safe in patients previously treated with natalizumab. Ther Adv Neurol Disord 2019;12:1756286419887596.","DOI":"10.1177\/1756286419887596"},{"issue":"2","key":"10.1007\/s13311-021-01037-2_bib21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"The Lancet Neurology."},{"key":"10.1007\/s13311-021-01037-2_bib22","article-title":"Immune-related genetic enrichment in frontotemporal dementia: an analysis of genome-wide association studies","volume":"15","author":"Broce","year":"2018","journal-title":"PLoS medicine."},{"key":"10.1007\/s13311-021-01037-2_bib23","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mabthera-epar-product-information_it.pdf."},{"key":"10.1007\/s13311-021-01037-2_bib24","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1212\/NXI.0000000000000463","article-title":"Monitoring B-cell repopulation after depletion therapy in neurologic patients","volume":"5","author":"Ellwardt","year":"2018","journal-title":"Neurology - Neuroimmunology Neuroinflammation."},{"issue":"12","key":"10.1007\/s13311-021-01037-2_bib25","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1212\/01.wnl.0000188907.97339.76","article-title":"Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia?","volume":"65","author":"Moreau","year":"2005","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01037-2_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Multiple sclerosis and related disorders."},{"key":"10.1007\/s13311-021-01037-2_bib27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s13311-019-00776-7","article-title":"Extending the interval of natalizumab dosing: is efficacy preserved?","volume":"17","author":"Clerico","year":"2020","journal-title":"Neurotherapeutics: J Amer Soc Exper NeuroTherapeutics"},{"key":"10.1007\/s13311-021-01037-2_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12610-016-0031-x","article-title":"Semen quality of 4480 young cancer and systemic disease patients: baseline data and clinical considerations","volume":"26","author":"Auger","year":"2016","journal-title":"Basic Clin Androl"},{"key":"10.1007\/s13311-021-01037-2_bib29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jnnp-2018-319208","article-title":"Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution","volume":"90","author":"Scarpazza","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-021-01037-2_bib30","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1148\/radiol.2015150673","article-title":"Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab: diagnostic precision with MR imaging","volume":"278","author":"Hodel","year":"2016","journal-title":"Radiology."},{"key":"10.1007\/s13311-021-01037-2_bib31","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1212\/WNL.0b013e3181a8266f","article-title":"Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells","volume":"72","author":"Kivis\u00e4kk","year":"2009","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01037-2_bib32","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.msard.2018.09.041","article-title":"Effectiveness and safety of rituximab in demyelinating diseases spectrum: an Italian experience","volume":"27","author":"D'Amico","year":"2019","journal-title":"Multi Scler Relat Dis"},{"key":"10.1007\/s13311-021-01037-2_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40893-016-0013-z","article-title":"Rituximab suppresses disease activity after natalizumab withdrawal: an exploratory study","volume":"1","author":"Malucchi","year":"2016","journal-title":"Multi Scler Demyelinating Dis"},{"key":"10.1007\/s13311-021-01037-2_bib34","doi-asserted-by":"crossref","unstructured":"Mancinelli CR, Scarpazza C, Cordioli C, et al. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab. Multi Scler J 2020:1352458520946017.","DOI":"10.1177\/1352458520946017"},{"key":"10.1007\/s13311-021-01037-2_bib35","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/14740338.2020.1807002","article-title":"Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review","volume":"19","author":"Ng","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1007\/s13311-021-01037-2_bib36","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1080\/03007995.2019.1585779","volume":"35","author":"Berardi","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1007\/s13311-021-01037-2_bib37","first-page":"35","article-title":"Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis","volume":"8","author":"Boyko","year":"2018","journal-title":"Degener Neurol Neuromuscul Dis."},{"key":"10.1007\/s13311-021-01037-2_bib38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Multi Scler Rel Dis"},{"key":"10.1007\/s13311-021-01037-2_bib39","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","volume":"265","author":"Ceronie","year":"2018","journal-title":"J Neurol"},{"key":"10.1007\/s13311-021-01037-2_bib40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2017.119","article-title":"Cladribine - an old newcomer for pulsed immune reconstitution in MS","volume":"13","author":"Wiendl","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-021-01037-2_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617753365","article-title":"Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study","volume":"11","author":"Comi","year":"2018","journal-title":"Ther Adv Neurol Disord."},{"key":"10.1007\/s13311-021-01037-2_bib42","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)."},{"key":"10.1007\/s13311-021-01037-2_bib43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21939","article-title":"Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?","volume":"67","author":"Bar-Or","year":"2010","journal-title":"Annals of neurology."},{"key":"10.1007\/s13311-021-01037-2_bib44","doi-asserted-by":"crossref","unstructured":"Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol (Baltimore, Md : 1950) 2014;193:580\u2013586.","DOI":"10.4049\/jimmunol.1400118"},{"key":"10.1007\/s13311-021-01037-2_bib45","doi-asserted-by":"crossref","unstructured":"Schuh E, Berer K, Mulazzani M, et al. Features of human CD3+CD20+ T cells. J Immunol (Baltimore, Md : 1950) 2016;197:1111\u20131117.","DOI":"10.4049\/jimmunol.1600089"},{"key":"10.1007\/s13311-021-01037-2_bib46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2307\/2533160","article-title":"Matching using estimated propensity scores: relating theory to practice","volume":"52","author":"Rubin","year":"1996","journal-title":"Biometrics."},{"key":"10.1007\/s13311-021-01037-2_bib47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/pds.986","article-title":"Weaknesses of goodness-of-fit tests for evaluating propensity score models: the case of the omitted confounder","volume":"14","author":"Weitzen","year":"2005","journal-title":"Pharmacoepidemiology Drug Saf"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01037-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01037-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01037-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:53:54Z","timestamp":1761807234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1878747923011558"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01037-2","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01037-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}